Use of dual mTOR inhibitor MLN0128 against everolimus-resistant breast cancer.

Karineh PetrossianDuc NguyenChiao LoNoriko KanayaGeorge SomloYvonne Xiaoyong CuiChiun-Sheng HuangShiuan Chen

Published in: Breast cancer research and treatment (2018)

Among the many signaling transduction pathways, which are altered post everolimus resistance, targeting dual mTORC1/2 is a possible option for patients who have recurrent disease from previous everolimus treatment.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
cancer therapy
young adults
combination therapy